Get the Stockscreener App
0.7708
0.80%
-0.0014
Lakeshore Biopharma Co Ltd stock is traded at $0.7708, with a volume of 22,074.
It is down -0.80% in the last 24 hours and up +64.73% over the past month.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
See More
Previous Close:
$0.7722
Open:
$0.8
24h Volume:
22,074
Relative Volume:
0.67
Market Cap:
$147.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+47.00%
1M Performance:
+64.73%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.755
$0.819
1-Week Range:
$0.53
$0.85
52-Week Range:
$0.3613
$0.9988
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
Name
Lakeshore Biopharma Co Ltd
Sector
Industry
Phone
-
Address
-
Lakeshore Biopharma Co Ltd Stock (LSB) Latest News
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - The Manila Times
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - StockTitan
LakeShore Biopharma names Xu Wang as new CEO - Investing.com India
LakeShore Biopharma names Xu Wang as new CEO By Investing.com - Investing.com Canada
LakeShore Biopharma Announces Leadership Transitions - Kilgore News Herald
LakeShore Biopharma Announces Leadership Transitions - StockTitan
Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update - Defense World
Short Interest in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Rises By 20.1% - Defense World
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Longview News-Journal
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - PR Newswire
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - Morningstar
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Simply Wall St
ROSEN, LEADING INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action InvestigationYS, SMIH - Marketscreener.com
LakeShore Biopharma (NASDAQ:LSB) Stock Quotes, Forecast and News Summary - Benzinga
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Macau Business
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Yahoo Finance UK
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Yahoo Finance
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough - Simply Wall St
LakeShore Biopharma Announces Executive ReshuffleTipRanks.com - TipRanks
The Hunt for Virus Treatments Continues Post Covid-19 - Exeter Lakeshore Times-Advance
Exploring High Insider Ownership In US Growth Companies - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): Are Analysts Optimistic? - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
Does Dun & Bradstreet Holdings (NYSE:DNB) Have A Healthy Balance Sheet? - Simply Wall St
YS, SMIH INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a ... - Marketscreener.com
YS Biopharma announces name change to 'LakeShore Biopharma'TipRanks.com - TipRanks
YS Biopharma to change legal name to LakeShore Biopharma (NASDAQ:YS) - Seeking Alpha
YS Biopharma Announces Name Change to LakeShore Biopharma USAEnglish - PR Newswire
YS Biopharma Announces Name Change to LakeShore Biopharma - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - Thailand Business News
YS Biopharma Approves Major Corporate ChangesTipRanks.com - TipRanks
YS Biopharma Announces Results of Extraordinary General Meeting APACEnglish - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
Arrow Electronics First Quarter 2024 Earnings: Misses Expectations - Simply Wall St
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 - PR Newswire
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PR Newswire
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine - PR Newswire
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility - PR Newswire
Sprinklr Full Year 2024 Earnings: EPS Beats Expectations - Simply Wall St
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 - PR Newswire
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. - PR Newswire
YS Biopharma Announces US$40 Million Private Placement Financing - PR Newswire
Sagimet Bio stock surges after trial win for NASH drug - Seeking Alpha
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - PR Newswire
ADIA-backed Lake Shore confident about turning around Koregaon Park mall - The Financial Express
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA - PR Newswire
Virtuous Retail in talks to sell malls for about $500 million - IndiaTimes
Lakeshore Biopharma Co Ltd Stock (LSB) Financials Data
There is no financial data for Lakeshore Biopharma Co Ltd (LSB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.16%
2.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):